Core Viewpoint - The article emphasizes the importance of proper cancer screening methods, highlighting that routine health check-ups do not equate to effective cancer screening, which can lead to missed diagnoses of serious conditions like cancer [1]. Group 1: Cancer Incidence in China - In 2022, the estimated incidence of the top 10 malignant tumors in China included 1,060,600 cases of lung cancer, 517,100 cases of colorectal cancer, and 466,100 cases of thyroid cancer, among others [2]. Group 2: Cancer Screening Recommendations - The article discusses the release of the "Recommendations for Screening and Prevention of Common Malignant Tumors in Residents (2025 Edition)" during the National Cancer Prevention and Control Week, which outlines high-risk groups and the "gold standards" for screening for over 20 types of malignant tumors [3]. Group 3: Specific Cancer Screening Guidelines - For colorectal cancer, the gold standard for screening is colonoscopy, with recommendations for starting at age 45 and conducting annual fecal immunochemical tests or colonoscopies every 5-10 years until age 75 [6]. - For breast cancer, mammography is the gold standard, with screening starting at age 40 and recommended every 1-2 years [9]. - For lung cancer, low-dose spiral CT is the gold standard for high-risk populations, suggesting screening for those aged 40 and above with a significant smoking history [12]. - For liver cancer, serum alpha-fetoprotein (AFP) and liver ultrasound are the gold standards, with recommendations for screening men over 35 and women over 45 every 6 months [17]. - For esophageal cancer, the gold standard is endoscopy, with recommendations for high-risk groups to undergo screening every 2 years [26]. - For cervical cancer, the gold standard includes cytology and high-risk HPV testing, with specific age-based recommendations for screening [34]. - For prostate cancer, serum PSA testing is the gold standard, recommended for men over 40 with a good health status [44]. - For bladder cancer, urine tests and ultrasound are the gold standards, with annual screening starting at age 70 for general risk populations [47]. - For kidney cancer, ultrasound and urine tests are the gold standards, with annual screening recommended for those over 50 [51]. - For thyroid cancer, clinical neck examination and ultrasound are the gold standards, with annual checks starting at age 30 [54]. - For skin cancer, clinical skin examinations and biopsies are the gold standards, with recommendations for high-risk individuals to undergo regular checks [73].

根据弗若斯特沙利文的资料， 觅瑞 是开发及商业化用于癌症及其他疾病早期检测 的、精准的、无 创的、可负担的、基于血液的miRNA检测试剂盒的先驱者与领导者 ； 根据弗若斯特沙利文的资料， 觅瑞 是全球为数不多的已获得分子癌症筛查行业IVD产品监管批准的公司之一，同时也是全球范围 内首家且唯一一家获得分子胃癌筛查IVD产品监管批准的公司。 今年上半年，核心产品GASTROClear的毛利率超80%。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，Mirxes Holding Company Limited（以下简称"觅瑞"）于11月4日更新招股 书，继续推进港交所主板上市进程，中金公司和建银国际担任联席保荐人。 成立于2014年的觅瑞作为一家起源于新加坡的微小核糖核酸("miRNA")技术公司，专注于在全球范 围内普及疾病筛查诊断解决方案。 截至2024年10月31日，觅瑞拥有一种核心产品(即GASTROClear)、两种其他商业化产品(即 LungClear及Fortitude)以及六种处于临床前阶段的候选产品。 其中，觅瑞的核心产品GASTROC ...